This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202959694/en/

Eurofins Medical Device Services is setting new standards with the industry's first GMP PFAS testing and advanced PFAS Risk Assessments for medical devices.
Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.
Eurofins Medical Device Services North America’s GMP PFAS testing and screening solution includes:
Eurofins Medical Device Services North America operates under ISO 17025 accreditation standards, and applies GMP best practices, ensuring sensitivity, specificity, and reproducibility even at trace levels.
Learn more at https://www.eurofins.com/medical-device/
About Eurofins Medical Device Services
Eurofins Medical Device Services offers comprehensive testing, consulting, and regulatory support for Class I, II, and III medical devices—including implants, instruments, single-use and combination products, and wearables.
With more than 40 years of experience, our global network of medical device testing laboratories and consultants provide strategic guidance from biological evaluation plans through commercialization, and specialize in international regulatory requirements, scientific trends, and tailored testing strategies.
Committed to global standards, Eurofins Medical Device Services designs and executes testing plans aligned with ISO, ASTM, ANSI, and AAMI standards, as well as custom methodologies. Our quality systems meet GMP and ISO 17025 requirements, helping clients accelerate market access with confidence.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202959694/en/
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.